ARTICLE | Company News
Merck, Allergan deal
July 13, 2015 7:00 AM UTC
Merck granted Allergan exclusive, worldwide rights to develop and commercialize MK-1602 and MK-8031 -- both oral calcitonin gene-related peptide (CGRP) receptor antagonists for migraines. Next year, A...